Putnam Investments LLC Sells 1,852 Shares of Theravance Biopharma, Inc. (NASDAQ:TBPH)

Putnam Investments LLC cut its stake in Theravance Biopharma, Inc. (NASDAQ:TBPH – Get Rating) by 1.8% during the third quarter, HoldingsChannel reports. The firm owned 102,156 shares of the biopharmaceutical company’s stock after selling 1,852 shares during the period. Putnam Investments LLC’s holdings in Theravance Biopharma were worth $1,036,000 at the end of the most recent quarter.

Other hedge funds have also recently made changes to their positions in the company. UBS Group AG grew its holdings in shares of Theravance Biopharma by 45.0% in the first quarter. UBS Group AG now owns 3,549 shares of the biopharmaceutical company’s stock worth $34,000 after purchasing an additional 1,101 shares during the last quarter. Royal Bank of Canada grew its holdings in shares of Theravance Biopharma by 1,330.7% in the third quarter. Royal Bank of Canada now owns 6,610 shares of the biopharmaceutical company’s stock worth $67,000 after purchasing an additional 6,148 shares during the last quarter. Quantbot Technologies LP bought a new position in shares of Theravance Biopharma in the second quarter worth about $62,000. Acadian Asset Management LLC grew its holdings in shares of Theravance Biopharma by 51.6% in the first quarter. Acadian Asset Management LLC now owns 8,277 shares of the biopharmaceutical company’s stock worth $77,000 after purchasing an additional 2,818 shares during the last quarter. Finally, Tower Research Capital LLC TRC grew its holdings in shares of Theravance Biopharma by 292.4% in the third quarter. Tower Research Capital LLC TRC now owns 9,877 shares of the biopharmaceutical company’s stock worth $100,000 after purchasing an additional 7,360 shares during the last quarter.

Wall Street Analysts Forecast Growth

Several brokerages have issued reports on TBPH. StockNews.com cut shares of Theravance Biopharma from a “buy” rating to a “hold” rating in a report on Tuesday, February 28th. SVB Leerink increased their target price on shares of Theravance Biopharma from $12.00 to $14.00 and gave the stock an “outperform” rating in a report on Thursday, November 17th. Finally, HC Wainwright reiterated a “buy” rating and set a $19.00 target price on shares of Theravance Biopharma in a report on Tuesday, February 28th.

Insider Buying and Selling at Theravance Biopharma

In other Theravance Biopharma news, CEO Rick E. Winningham sold 50,000 shares of the stock in a transaction dated Wednesday, December 14th. The shares were sold at an average price of $11.19, for a total transaction of $559,500.00. Following the completion of the sale, the chief executive officer now directly owns 1,350,797 shares of the company’s stock, valued at $15,115,418.43. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Insiders own 4.80% of the company’s stock.

Theravance Biopharma Price Performance

Shares of Theravance Biopharma stock opened at $10.25 on Tuesday. Theravance Biopharma, Inc. has a 1 year low of $7.53 and a 1 year high of $11.83. The firm’s 50-day moving average is $10.59 and its two-hundred day moving average is $10.39. The stock has a market cap of $644.32 million, a price-to-earnings ratio of 0.89 and a beta of 0.51.

Theravance Biopharma Company Profile

(Get Rating)

Theravance Biopharma, Inc is a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small molecule drugs designed to better meet patient needs. Its research is focused in the areas of inflammation and immunology.
In pursuit of its purpose, Theravance Biopharma applies insights and innovation at each stage of its business and utilizes its internal capabilities and those of partners around the world.